Midostaurin
Back to searchMolecule Structure
Scientific Name
Midostaurin
Description of the Drug
Midostaurin is an antineoplastic agent used to treat high-risk acute myeloid leukemia (AML) with specific mutations, aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06595
http://www.drugbank.ca/drugs/DB06595
Brand Name(s)
Rydapt
Company Owner(s)
Novartis Pharmaceuticals Corp
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Tyrosine-protein kinase receptor FLT3 | SINGLE PROTEIN | INHIBITOR | CHEMBL1974 |
Stem cell growth factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL1936 |
Protein kinase C (PKC) | PROTEIN FAMILY | INHIBITOR | CHEMBL2093867 |
Platelet-derived growth factor receptor | PROTEIN COMPLEX | INHIBITOR | CHEMBL2095189 |
Vascular endothelial growth factor receptor 2 | SINGLE PROTEIN | INHIBITOR | CHEMBL279 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL8295379 | |
DrugBank | DB06595 | |
PubChem: Thomson Pharma | 14788708 | 14935507 |
PubChem | 9829523 | |
LINCS | LSM-2287 | |
Nikkaji | J1.312.230J | |
PDBe | 2K2 | |
BindingDB | 50326053 | |
DrugCentral | 5231 | |
Brenda | 216818 | 146800 |
ChemicalBook | CB71315281 | |
Guide to Pharmacology | 5702 | |
rxnorm | RYDAPT | MIDOSTAURIN |
PubChem: Drugs of the Future | 22395186 | |
ChEBI | 63452 | |
ZINC | ZINC000100013130 |